Wordt geladen...
贝伐珠单抗在晚期非小细胞肺癌一线治疗中的研究进展
As the first anti-angiogenesis monoclonal antibody, bevacizumab has been an vital component of front line regimen of advanced nonsqaumous non-small cell lung cancer (NSCLC). It increase the efficacy of chemotherapy, epithelial growth factor receptor tyrosine kinase inhibitors and immune checkpoint i...
Bewaard in:
| Gepubliceerd in: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
中国肺癌杂志编辑部
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7406442/ https://ncbi.nlm.nih.gov/pubmed/32702797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.34 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|